The impact of CDH13 polymorphism and statin administration on TG/HDL ratio in cardiovascular patients

Jung Ran Choi, Yangsoo Jang, Sungjoo Kim Yoon, Jong Keun Park, Sungbin Richard Sorn, Mi Young Park, Myoungsook Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Adiponectin is expressed in adipose tissue, and is affected by smoking, obesity, and genetic factors, such as CDH13 polymorphism, contributing to the development of coronary vascular diseases (CVDs). Materials and Methods: We investigated the effect of genetic variations of CDH13 (rs3865188) on blood chemistry and adiponectin levels in 345 CVD patients undergoing statin-free or statin treatment. Results: Genetic variation in CDH13 was significantly correlated with several clinical factors, including adiponectin, diastolic blood pressure, triglyceride (TG), and insulin levels. Subjects with the T allele (mutant form) had significantly lower adiponectin levels than those with the A allele. Total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), TG/high-density lipoprotein cholesterol (HDLc) ratio, and HDL3b subtype were markedly decreased in statin treated subjects regardless of having the A or T allele. TG and TG/HDL in the statin-free group with TT genotype of the rs3865188 was higher than in the others but they were not different in the statin-treated subjects. We observed a significant difference in adiponectin levels between patients with the A and T alleles in the statin-free group; meanwhile, no difference in adiponectin levels was noted in the statin group. Plasma levels of other cytokines, leptin, visfatin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), were not different among the CDH13 genotypes according to statin administration. Body mass index (BMI), TG, insulin, HDL3b, and TG/HDL ratio showed negative correlations with adiponectin levels. Conclusion: Plasma adiponectin levels and TG/HDL ratio were significantly different according to variants of CDH13 and statin administration in Korean patients with CVD.

Original languageEnglish
Pages (from-to)1604-1612
Number of pages9
JournalYonsei medical journal
Volume56
Issue number6
DOIs
Publication statusPublished - 2015 Nov

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Adiponectin
Triglycerides
Alleles
Vascular Diseases
Coronary Disease
Genotype
Nicotinamide Phosphoribosyltransferase
Insulin
Blood Pressure
Leptin
LDL Cholesterol
HDL Cholesterol
Adipose Tissue
Interleukin-6
Body Mass Index
Tumor Necrosis Factor-alpha
Obesity
Smoking
Cholesterol

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Choi, Jung Ran ; Jang, Yangsoo ; Yoon, Sungjoo Kim ; Park, Jong Keun ; Sorn, Sungbin Richard ; Park, Mi Young ; Lee, Myoungsook. / The impact of CDH13 polymorphism and statin administration on TG/HDL ratio in cardiovascular patients. In: Yonsei medical journal. 2015 ; Vol. 56, No. 6. pp. 1604-1612.
@article{cda270f9b6bf4c109f3d6cd0d4401675,
title = "The impact of CDH13 polymorphism and statin administration on TG/HDL ratio in cardiovascular patients",
abstract = "Purpose: Adiponectin is expressed in adipose tissue, and is affected by smoking, obesity, and genetic factors, such as CDH13 polymorphism, contributing to the development of coronary vascular diseases (CVDs). Materials and Methods: We investigated the effect of genetic variations of CDH13 (rs3865188) on blood chemistry and adiponectin levels in 345 CVD patients undergoing statin-free or statin treatment. Results: Genetic variation in CDH13 was significantly correlated with several clinical factors, including adiponectin, diastolic blood pressure, triglyceride (TG), and insulin levels. Subjects with the T allele (mutant form) had significantly lower adiponectin levels than those with the A allele. Total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), TG/high-density lipoprotein cholesterol (HDLc) ratio, and HDL3b subtype were markedly decreased in statin treated subjects regardless of having the A or T allele. TG and TG/HDL in the statin-free group with TT genotype of the rs3865188 was higher than in the others but they were not different in the statin-treated subjects. We observed a significant difference in adiponectin levels between patients with the A and T alleles in the statin-free group; meanwhile, no difference in adiponectin levels was noted in the statin group. Plasma levels of other cytokines, leptin, visfatin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), were not different among the CDH13 genotypes according to statin administration. Body mass index (BMI), TG, insulin, HDL3b, and TG/HDL ratio showed negative correlations with adiponectin levels. Conclusion: Plasma adiponectin levels and TG/HDL ratio were significantly different according to variants of CDH13 and statin administration in Korean patients with CVD.",
author = "Choi, {Jung Ran} and Yangsoo Jang and Yoon, {Sungjoo Kim} and Park, {Jong Keun} and Sorn, {Sungbin Richard} and Park, {Mi Young} and Myoungsook Lee",
year = "2015",
month = "11",
doi = "10.3349/ymj.2015.56.6.1604",
language = "English",
volume = "56",
pages = "1604--1612",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

The impact of CDH13 polymorphism and statin administration on TG/HDL ratio in cardiovascular patients. / Choi, Jung Ran; Jang, Yangsoo; Yoon, Sungjoo Kim; Park, Jong Keun; Sorn, Sungbin Richard; Park, Mi Young; Lee, Myoungsook.

In: Yonsei medical journal, Vol. 56, No. 6, 11.2015, p. 1604-1612.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of CDH13 polymorphism and statin administration on TG/HDL ratio in cardiovascular patients

AU - Choi, Jung Ran

AU - Jang, Yangsoo

AU - Yoon, Sungjoo Kim

AU - Park, Jong Keun

AU - Sorn, Sungbin Richard

AU - Park, Mi Young

AU - Lee, Myoungsook

PY - 2015/11

Y1 - 2015/11

N2 - Purpose: Adiponectin is expressed in adipose tissue, and is affected by smoking, obesity, and genetic factors, such as CDH13 polymorphism, contributing to the development of coronary vascular diseases (CVDs). Materials and Methods: We investigated the effect of genetic variations of CDH13 (rs3865188) on blood chemistry and adiponectin levels in 345 CVD patients undergoing statin-free or statin treatment. Results: Genetic variation in CDH13 was significantly correlated with several clinical factors, including adiponectin, diastolic blood pressure, triglyceride (TG), and insulin levels. Subjects with the T allele (mutant form) had significantly lower adiponectin levels than those with the A allele. Total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), TG/high-density lipoprotein cholesterol (HDLc) ratio, and HDL3b subtype were markedly decreased in statin treated subjects regardless of having the A or T allele. TG and TG/HDL in the statin-free group with TT genotype of the rs3865188 was higher than in the others but they were not different in the statin-treated subjects. We observed a significant difference in adiponectin levels between patients with the A and T alleles in the statin-free group; meanwhile, no difference in adiponectin levels was noted in the statin group. Plasma levels of other cytokines, leptin, visfatin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), were not different among the CDH13 genotypes according to statin administration. Body mass index (BMI), TG, insulin, HDL3b, and TG/HDL ratio showed negative correlations with adiponectin levels. Conclusion: Plasma adiponectin levels and TG/HDL ratio were significantly different according to variants of CDH13 and statin administration in Korean patients with CVD.

AB - Purpose: Adiponectin is expressed in adipose tissue, and is affected by smoking, obesity, and genetic factors, such as CDH13 polymorphism, contributing to the development of coronary vascular diseases (CVDs). Materials and Methods: We investigated the effect of genetic variations of CDH13 (rs3865188) on blood chemistry and adiponectin levels in 345 CVD patients undergoing statin-free or statin treatment. Results: Genetic variation in CDH13 was significantly correlated with several clinical factors, including adiponectin, diastolic blood pressure, triglyceride (TG), and insulin levels. Subjects with the T allele (mutant form) had significantly lower adiponectin levels than those with the A allele. Total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), TG/high-density lipoprotein cholesterol (HDLc) ratio, and HDL3b subtype were markedly decreased in statin treated subjects regardless of having the A or T allele. TG and TG/HDL in the statin-free group with TT genotype of the rs3865188 was higher than in the others but they were not different in the statin-treated subjects. We observed a significant difference in adiponectin levels between patients with the A and T alleles in the statin-free group; meanwhile, no difference in adiponectin levels was noted in the statin group. Plasma levels of other cytokines, leptin, visfatin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), were not different among the CDH13 genotypes according to statin administration. Body mass index (BMI), TG, insulin, HDL3b, and TG/HDL ratio showed negative correlations with adiponectin levels. Conclusion: Plasma adiponectin levels and TG/HDL ratio were significantly different according to variants of CDH13 and statin administration in Korean patients with CVD.

UR - http://www.scopus.com/inward/record.url?scp=84944128602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944128602&partnerID=8YFLogxK

U2 - 10.3349/ymj.2015.56.6.1604

DO - 10.3349/ymj.2015.56.6.1604

M3 - Article

C2 - 26446643

AN - SCOPUS:84944128602

VL - 56

SP - 1604

EP - 1612

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -